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The concept of differentiation therapy of cancer is ~40 years old. Despite many encour-
aging results obtained in laboratories, both in vitro and in vivo studies, the only really
successful clinical application of differentiation therapy was all-trans-retinoic acid (ATRA)-
based therapy of acute promyelocytic leukemia (APL). ATRA, which induces granulocytic
differentiation of APL leukemic blasts, has revolutionized the therapy of this disease by
converting it from a fatal to a curable one. However, ATRA does not work for other acute
myeloid leukemias (AMLs). Since 1,25-dihydroxyvitamin D3 (1,25D) is capable of inducing
monocytic differentiation of leukemic cells, the idea of treating other AMLs with vitamin
D analogs (VDAs) was widely accepted. Also, some types of solid cancers responded to
in vitro applied VDAs, and hence it was postulated that VDAs can be used in many clinical
applications. However, early clinical trials in which cancer patients were treated either with
1,25D or with VDAs, did not lead to conclusive results. In order to search for a molecu-
lar basis of such unpredictable responses of AML patients toward VDAs, we performed
ex vivo experiments using patient’s blast cells. Experiments were also performed using
1,25D-responsive and 1,25D-non-responsive cell lines, to study their mechanisms of resis-
tance toward 1,25D-induced differentiation. We found that one of the possible reasons
might be due to a very low expression level of vitamin D receptor (VDR) mRNA in resistant
cells, which can be increased by exposing the cells to ATRA. Our considerations concern-
ing the molecular mechanism behind the low VDR expression and its regulation by ATRA
are reported in this paper.
Keywords: cancer, differentiation, leukemia, all-trans-retinoic acid, 1,25-dihydroxyvitamin D3, vitamin D receptor,
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DIFFERENTIATION THERAPY OF CANCER
Cancer remains one of the leading causes of morbidity and mortal-
ity worldwide despite many improvements in diagnostic and ther-
apeutic strategies. Development of cancer is a multi-step process
which usually involves sustained proliferative potential, evading
of growth-suppressing signals, resisting apoptosis, and enabling
replicative immortality of the cell, due to gene aberrations and
deregulated expression of genes (1). Recent development in the
field of biological sciences along with a better understanding of
the biology of cancer cell and its microenvironment, has led to
new treatment methods. One such method is the targeted therapy,
where new generation of cancer drugs is designed to interfere with
a specific molecular target that is believed to have an important
role in cell growth, survival, and differentiation and restore the dif-
ferentiation capacity. This novel and less toxic form of therapy was
designed to reprogram cancer cells, which resulted in the loss of
proliferative capacity and induction of terminal differentiation or
apoptosis of the cells (2). Classical chemotherapy involved killing
of cells that divided rapidly (one of the main properties of cancer
cells), which also killed cells that divided rapidly under normal
circumstances, like bone marrow stem cells or cells in digestive
tract. Hence, this method was highly toxic, which resulted in high
death rates in cancer patients (3).
One particular type of cancer, with increasing incidence is acute
myeloid leukemia (AML). AML is characterized by the accumula-
tion of transformed primitive hematopoietic blast cells, which lose
their ability of normal differentiation and proliferation (4). The
studies conducted on characterization of the gene mutations and
aberrant signaling pathways have provided insights into the mech-
anisms of leukemogenesis. Targeted therapy in AML was proposed
in late twentieth century by Leo Sachs, which focused on forcing
cancer cells to differentiate (5). This was a result of several in vitro
analyses made in 1970s and 1980s, which showed that a number of
compounds have anti-proliferative and pro-differentiating prop-
erties toward AML cells. For example, Breitman et al. showed that
granulocytic differentiation of HL60 leukemic cells was possible
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after all-trans-retinoic acid (ATRA) treatment, which resulted in
the rapid development of differentiation therapies and a better
understanding of the differentiation mechanisms involved (6).
This was because many cancer subtypes displayed alternations in
the normal program of differentiation and growth. Hence, the use
of specific agents that can trigger differentiation of leukemic cells
along normal hematopoietic lineages became necessary (5).
RETINOIDS IN THE TREATMENT OF ACUTE MYELOID
LEUKEMIA
The above observations were translated into differentiation ther-
apy, using ATRA in acute promyelocytic leukemia (APL) (7, 8).
Pathogenesis of APL is associated with a chromosomal transloca-
tion that disrupts retinoic acid receptor α (RARα) gene located on
the short arm of chromosome 17 (q21) and results in an arrest
of the early stage of granulocytic differentiation (promyelocyte)
(9). A balanced translocation between chromosomes 15 and 17
[t(15;17)(q22;q21)] (10), which leads to the formation of fusion
of promyelocytic leukemia protein (PML) and RARα was found
in 98% of APL patients. It was also shown that a small subset of
patients carry other variants of 17q chromosome translocation
(Table 1) (11, 12).
All cytogenetic aberrations found in APL are connected with
RARα gene, which plays a central role in APL pathogenesis
(11). Three forms of RAR, namely RARα, RARβ, and RARγ, are
found to be important regulators of myeloid differentiation (13),
which share structural similarity in their ligand and DNA-binding
domains, but display distinct tissue-specific pattern of expression.
When dimerized with a retinoid X receptor (RXR), RARs bind to
specific promoter sequences upstream of genes (direct response
elements – DRs) and promote their transcription in the presence
of ATRA or 9-cis-RA. In the absence of a ligand, RAR/RXR het-
erodimers interact with nuclear receptor co-repressors (SMRT and
N-CoR), that recruit histone deacetylases (HDACs) and induce
chromatin condensation and repression of transcription (14).
Retinoic acid receptor α, a principal mediator of retinoic acid
(RA) activity (15) regulates several genes involved in myeloid
differentiation including transcription factor PU.1 (16, 17) and
CCAAT/enhancer-binding proteins (C/EBPs): C/EBPβ (18) and
C/EBPε (19). A second protein involved in the t(15;17) transloca-
tion is PML, a key organizer of nuclear bodies (NBs) that are bound
Table 1 |Variant translocations in APL [based on Ref. (11) and
http://atlasgeneticsoncology.org/index.html].
Translocation Translocation partner Epidemiology
t(11;17)
(q23;q21)
PLZF (promyelocytic
leukemia zinc-finger protein)
1% of APL patients
t(5;17)
(q35;q21)
NPM1 (nucleophosmin 1) Exceptional (only two
well-documented cases)
t(11;17)
(q13;q21)
NUMA (nuclear mitotic
apparatus)
Exceptional (only one
case fully described)
der(17) Stat5b (signal transducer and
activator of transcription)
Exceptional (only one
case fully described)
to chromatin (20). Wild-type PML has a speckled nuclear pattern
of expression, while PML/RARα has mostly a micropunctuated
nuclear pattern or a cytoplasmic localization (21). PML regu-
lates various cellular processes like defense against viral infection,
DNA-damage, oxidative stress (22), regulation of transcription,
heterochromatin remodeling, post-translational modification of
proteins (23), and p53 signaling (24). PML is also an early medi-
ator of transcription in myelopoiesis (25). Treatment of APL cells
with RA caused reformation of normal NBs (21), which was caused
by RA-induced degradation of a fusion protein, and in its absence
the formation of NBs by proper PML protein resulting from the
second, not mutated allele (26).
The fusion protein resulting from translocation t(15;17) always
contains the N-terminal part of PML and the C-terminal part
of RARα. The N-terminal part of PML is highly variable among
patients and consists mostly of coiled-coil domain and dimeriza-
tion domain. The C-terminal part of RARα contains dimerization,
DNA, and ligand-binding domains and both transcriptional acti-
vating and repressing domains (27, 28). One of the most impor-
tant features of the fusion protein as an oncogenic factor is the
way it influences transcription. PML–RARα forms homodimers,
through PML coiled-coil domains, which blocks the conforma-
tional changes associated with the release of co-repressors (SMRT
and N-CoR), methyltransferase, and HDACs (29), thereby lead-
ing to histone H3 modifications (24). Thus, the altered RARα
has lost its potential to respond to physiological concentrations
of ATRA and acts as a constitutive repressor leading to RARα
signaling block, resulting in inhibition of differentiation of APL
cells (29). Moreover, PML–RARα is capable of antagonizing the
transactivation function of wild-type RARα on RA-inducible pro-
moters, and contributes to leukemogenesis by interfering with the
process of differentiation (9).
Promyelocytic leukemia protein–RARα also heterodimerizes
with wild-type PML, disrupting its localization in NBs (24). The
best-known post-translational modification of PML is sumoy-
lation. This modification stabilizes PML in NBs, which affects
other PML-bound proteins and recruits transcriptional repressors
(20). It is suggested that sumoylated PML in the fusion protein
PML–RARα, might recruit repressors of transcription, leading
to even stronger repression which cannot be reversed by phys-
iological concentrations of ATRA (30). Experiments on mouse
models have shown that the loss of second allele results in pro-
gression of the disease (31), which suggests that PML inactivation
increases the transforming potential of PML–RARα by binding
proteins involved in chromatin remodeling and transcriptional
repression (32). In some cases of ATRA-resistant APL, the sec-
ond allele of PML gene is mutated which causes accumulation of
PML in cytoplasm, stabilization of PML–RARα, and inhibition of
differentiation (33). The above data suggest that both RARα and
PML play significant roles in the pathogenesis of leukemia (34).
In testing the role of PML–RARα in mediating the sensitivity
of leukemic cells to ATRA, it was hypothesized that ATRA could
influence C/EBP proteins, which are members of leucine zipper
transcription factor family. Their ability to bind to DNA and reg-
ulate cell fate by mediating protein–protein interactions have been
shown to be responsible for their effect on cell proliferation and
differentiation (35). So far, C/EBPα, C/EBPβ, and C/EBPε have
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been reported to be involved at various stages of myeloid devel-
opment and also responsible for transcription of genes important
for blood cells’ functions (19, 36–42). Studies conducted on the
mechanism of differentiation of APL cells by ATRA, demonstrated
an increase in C/EBPβ RNA and protein levels (corresponding to
increased C/EBPβ activity). This C/EBPβ activity was found to be
controlled by PML–RARα, through C/EBPβ proximal promoter
and was found to be absent in cells that were found to be resistant
to ATRA (18). In vitro studies also demonstrated that transcrip-
tion factor PU.1 was suppressed in cells carrying the PML–RARα
fusion protein and that ATRA-induced granulopoiesis in these cells
involved restoring the level of PU.1 (17). It appeared that induc-
tion of PU.1 by ATRA was possible only when the levels of C/EBP
proteins were upregulated enough to activate the PU.1 promoter.
This led to the conclusion that PU.1, an ATRA responsive gene is
capable of overcoming the inhibition mediated by PML–RARα in
the promoter region of PU.1 (17).
Recent experiments have shown that oncogenic transformation
mediated by PML–RARα is a multi-step process, and does not
take place just by repression of transcription. It was shown that
unlike the wild-type RXR–RARαwhich recognizes DR1, DR2, and
DR5 sequences, fusion protein PML–RARα has a broad range of
response elements due to the presence of four DNA-binding sites
(DR1–DR16) (43). Binding of RXR facilitates the binding of PML–
RARα complex to widely spaced direct repeats resulting in a larger
spectrum of controlled genes, causing a transcription deregula-
tion in APL cells (43, 44). Moreover, it appeared that one of the de
novo binding partners for the fusion protein is vitamin D receptor
(VDR) and by sequestering it, PML–RARα causes the inhibition of
1,25-dihydroxyvitamin D3 (1,25D)-induced differentiation (45).
Treatment of APL patients with pharmacological doses of
ATRA causes differentiation of APL cells toward granulocytes. At
a molecular level, ATRA reverses the differentiation block by inter-
acting with the ligand-binding domain of RARα, which leads to
the release of co-repressors and the activation of genes responsible
for transcription. After ATRA treatment, mature granulocyte-like
cells enter programed cell death (46). Higher clinical efficiency in
APL patients is achieved by a combination of ATRA with arsenic
trioxide (ATO), which induces apoptosis through the mitochon-
drial pathway and by the formation of reactive oxygen species
(ROS) (47). ATO has a limited differentiation capacity which
is partial (48) and dose-dependent (49), most probably medi-
ated by histone acetylation and transcriptional activation of many
differentiation-related genes (50).
However, the most important effects of both ATRA and ATO
treatment consist in degradation of PML–RARα (51). As it was
presented in the past, wild-type RARα, as well as PML–RARα
fusion, become degraded upon the treatment of the cells with
RA (52). On the other hand, ATO targets the normal PML pro-
tein and PML–RARα fusion to proteasome-mediated degradation
(53). This is mediated mostly by an ATO-induced oxidative stress,
which leads to the cross-linking of PML proteins by disulfide
bonds. PML consequently aggregates at the outer shell of NBs,
the aggregates become massively sumoylated and are targeted to
proteasome-mediated degradation (54). However, proteasome-
mediated degradation is not the only mechanism of clearance
of PML–RARα fusion protein in response to either RA or ATO
treatment. As it was presented, both agents trigger the process of
autophagy in APL cells, contributing to the degradation of the
oncoprotein (55). Since both RA and ATO contribute to degrada-
tion of PML–RARα, their simultaneous use gives synergistic effects
in clearance of APL blasts (51).
Also,clinical experiences have proven that ATRA and ATO treat-
ments are synergistic and very efficient, converting APL from a fatal
into a curable disease (56). When described for the first time, APL
was considered the most aggressive form of AML, where death
was caused predominantly by sudden hemorrhages resulting from
coagulation disorders (57). The very first paper describing the
use of ATRA to treat APL patients reported that all 24 patients
involved in the study attained complete remission, which was rev-
olutionary (7). Unfortunately, all of the patients from this initial
group experienced a relapse of the disease (56) and, it was reported
later that some of the patients, who relapsed after ATRA treat-
ment, developed ATRA resistance (58). The next step forward
led to the introduction of a combination therapy composed of
ATRA and idarubicin, which led to molecular remission in 98% of
patients, and 79% 2-year event-free survival rates (59). Although
the remission rates obtained with ATRA and idarubicin were very
high, the introduction of ATO (60) produced even better out-
comes. The recent multicenter study, which compared the ATRA
plus chemotherapy (idarubicin, mitoxantrone, methotrexate, and
6-mercaptopurine) with ATRA plus ATO in patients with APL,
revealed that 2-year event-free survival rates were 97% in the
ATRA–ATO group and 86% in the ATRA–chemotherapy group
(61), showing that new paradigms of APL therapy should be
introduced (62).
DIFFERENTIATION OF NON-APL AMLs
Another type of AML where differentiation therapy might be
useful is AML-M2 with translocation t(8;21)(q21;q22). This aber-
ration leads to the fusion of acute myeloid leukemia 1 (AML1)
protein and the eight-twenty-one (ETO) protein (63). Normal
AML1 functions as a transcriptional activator, promoting granu-
locytic differentiation through the upregulation of lineage-specific
target genes, while ETO protein (nuclear factor) possessing a
self-associating domain, acts as a transcriptional repressor by
recruiting HDAC complex (64). The fusion protein consists of the
N-terminal DNA-binding domain of AML1 protein and almost
entire ETO protein, with self-association and nuclear co-repressor
interacting regions which influences multiple processes including
myelomonocytic development (63). After fusion with ETO repres-
sor protein,AML1 turns from being an activator to repressor which
downregulates all of its target genes involved in granulocytic dif-
ferentiation (64) through recruitment of co-repressors complex
containing HDAC activity (65).
The AML1–ETO and PML–RARα share several common fea-
tures, suggesting similar pathogenic mechanism in AML cells. Both
are found to form oligomeric complexes with the increased affinity
for HDACs, and act as transcriptional repressors of differentiation-
related genes. RA signaling pathway is silenced in AML1–ETO
AMLs through recruitment of HDACs on regulatory sites, result-
ing in the transcriptional silencing of the RARβ2 gene which leads
to RA resistance and differentiation block (66). AML1–ETO also
interacts with essential hematopoietic transcription factors such
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as C/EBPα, PU.1, and GATA1 and blocks their differentiation-
promoting functions (64). The oncoprotein also interferes directly
with RARα by binding to the receptor in a ligand-independent
manner, thus blocking the ability of ATRA to mediate the co-
regulator exchange and preventing activation of RARα target gene
expression (63).
Novel differentiation agents for AML1–ETO positive AML are
targeted toward HDACs, which are capable of modifying the his-
tone acetylation status by removing acetyl groups, thus leading to
chromatin silencing. Unlike chromosomal abnormalities or gene
mutations which cause loss of gene function, silencing of the chro-
matin can be pharmacologically reversed by HDACs inhibitors.
These compounds are promising agents that promote histone
hyperacetylation, leading to chromatin relaxation and expression
of genes important for normal cell growth and differentiation (67).
HDACs inhibitors together with ATRA are used in ATRA-resistant
APL with translocation PZLF–RARα (68), where HDACs sensi-
tize cells to ATRA treatment (69). Since changing the silenced
chromatin into an open form is a multi-step reaction, involving
not only the release of HDACs but also the recruitment of chro-
matin remodeling complexes and transcriptional co-activators, the
inhibition of HDACs seems to be only an initial step and is not
sufficient enough to restore the complete cell differentiation (69).
Therefore, a combination therapy could be beneficial for patients
with AML1–ETO, where the RA pathway is repressed.
Another promising target in differentiation therapy is peroxi-
some proliferator activated receptor γ (PPARγ), which belongs to
the nuclear receptor family and functions as a ligand-dependent
transcription factor responsible for lipid metabolism (70). This
nuclear receptor is a putative cancer therapy target, because it
controls the expression of genes which are important for cell fate,
for example genes involved in cell cycle regulation: p21Waf1/Cip1,
p18INK4c (71), and β-catenin which is a key downstream compo-
nent of the canonical Wnt signaling pathway (71, 72). The receptor
is not only expressed in adipocytes but also in many other tis-
sues and cell types throughout the body, including monocytes and
macrophages (70). Furthermore, it was shown that the level of
expression of PPARγ is higher in leukemic cell lines than in normal
blood cells (73). Myelomonocytic leukemic cells express abundant
PPARγ, and its ligands can force acute myelomonocytic leukemic
cells to differentiate toward macrophages (74). It was shown that
the PPARγ ligand (troglitazone) can inhibit clonal proliferation
of myeloid monocytic leukemic cells U-937 when combined with
ATRA and/or RXR ligands. All three tested compounds exhibited
synergistic induction of differentiation with reduced viability of
human myeloid leukemia cell lines (73).
Retinoid X receptor is yet another important target in AML.
RXRs are receptors for vitamin A metabolites like 9-cis-RA and
are the binding partners required for transcriptional activation
by some other members of the steroid/thyroid hormone receptor
superfamily, including RARs, VDR, and PPARs (75). RXR antago-
nists could become novel therapeutic agents for the treatment of
AML. Studies using HL60 cells and leukemic patients’ cells showed
that RXR antagonist (bexarotene) inhibits growth and induces dif-
ferentiation of cells toward neutrophils. Phase I clinical trials using
bexarotene in non-APL patients have shown that costimulation of
both RAR and RXR receptors may be involved in differentiation of
non-APL AML. It was suggested that differentiation in APL may
occur through the RAR pathway while in non-APL similar effects
may be achieved through RXR (76).
1,25-DIHYDROXYVITAMIN D3
A very promising differentiation effect was demonstrated by the
physiologically active form of vitamin D, namely 1,25D. The pri-
mary function of this secosteroid compound is to maintain the
calcium and phosphorus homeostasis (77, 78). In addition, non-
classical functions of 1,25D include: regulation of the immune
response, influence on proliferation, maturation, and apoptosis of
normal and neoplastic cells (77, 79–83). Several studies demon-
strated the antitumor and pro-differentiating activity of 1,25D on
cancer cells (82, 84–86), which led to early clinical trials to test
the ability of 1,25D to treat AML and myelodysplastic syndromes
(MDS) (82, 87).
The first discovery of the use of physiologically active form of
vitamin D to induce the differentiation of AML promyeloid cell
line HL60, into the cells resembling monocytes was done in 80s
of twentieth century (88), during which it was shown that expo-
sure to 1,25D can induce the ability of these cells to phagocytose
and can inhibit proliferation. In due course, it was found that
many other myeloid cell lines such as promonocytoid U937 and
THP-1 also responded to 1,25D by exhibiting a decreased ability
to proliferate and displaying many features of mature monocytes
(89). MV4–11 and MOLM-13 cells, with mutated Fms-like tyro-
sine kinase 3 (FLT3) responded to 1,25D treatment by expressing
cell differentiation markers, which was although lesser than in the
model HL60 cell line (90).
On examining the mechanisms involved in the induction of
differentiation by 1,25D, it was found that it exerts its effects by
binding to a nuclear receptor called VDR. In the ligand-bound
state, VDR heterodimerizes with RXR and attaches itself to the
promoter regions of the target genes, such as osteocalcin (91),
24-hydroxylase of 1,25D (CYP24A1) (92, 93), kinase suppressor
of Ras-1 (94), p27Kip1 (95), or CD14 (96) which play important
roles in regulating the calcium–phosphate homeostasis, metab-
olism of 1,25D, cellular differentiation, and cell cycle. Except the
well-known activation of VDR protein, which confers the so-called
“genomic pathway of signal transduction,” 1,25D activates mem-
brane initiated signaling pathways, known as “rapid responses,”
such as MAPK pathways (97), the lipid signaling pathways (98),
or PI3K–AKT pathway (99, 100). Induction of cell cycle arrest by
influencing genes responsible for anti-proliferation, such as inter-
feron α-inducible protein p27 (IFI27) (101) and p21 (102) has
been found to be one of the main anti-proliferative actions of
1,25D. The pro-differentiating effect is mediated by transcription
factors crucial for myeloid hematopoiesis and includes transient
upregulation of C/EBPα and sustained upregulation of C/EBPβ
(103). The initiation of differentiation in HL60 cells, was observed
by a rapid growth followed by growth arrest and accompanied
by a monocytic differentiation (104). This was in common with
U937 cells which after initial proliferative burst, later showed ele-
vated levels of cyclin-dependent kinase inhibitors, p21Waf1/Cip1 and
p27Kip1 (105). Other mechanisms include a decrease in the level
of gene expression of exportin and importins (which are involved
in regulating the traffic of substrates for protein production)
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(106) and elf2 (a translation initiation factor) (107) in HL60
cells suggesting decreased protein synthesis and suppression of
translation.
CLINICAL TRIALS USING VITAMIN D COMPOUNDS IN THE
TREATMENT OF ACUTE MYELOID LEUKEMIA
The in vitro studies described above led to nine studies, which
examined the effects of different vitamin D compounds, such as
1,25D or 1-hydroxyvitamin D3 (alfacalcidol; precursor of 1,25D)
in AML patients, either alone or in combination with other agents
such as cytarabine, RA, hydroxyurea, or interferon α. These studies
were conducted on small groups ranging from 1 to 29 patients with
AML, where vitamin D compounds induced partial differentiation
and the results were modest (Table 2) (108–116). It is important to
note that all these studies used different dose schedules and some
patients developed hypercalcemia, which was recently exhaustively
reviewed (117). The doses of vitamin D compounds ranged from
0.5 to 15µg/day in the above clinical trials. In the first clinical trial,
alfacalcidol was used at the doses ranging from 4.5 to 15µg/day
and two out of three patients (one patient suffered from MDS)
developed transient hypercalcemia which showed that this is a
common side effect of vitamin D treatment (109). In the later
studies, alfacalcidol and 1,25D were administrated at doses from
0.25 to 1µg/day to avoid hypercalcemia (117). This reinforced
the need to synthesize vitamin D analogs (VDAs) with decreased
calcemic activity and greater antitumor activity (85, 118, 119).
Several in vitro studies have shown that the biological effects
of 1,25D can be selectively modulated in combination with other
drugs (86, 120, 121). Slapak et al. presented promising results from
the study conducted on 29 patients who were treated with cytara-
bine, hydroxyurea, and 1,25D, showing an overall response of 79%
where 45% was complete remission and 34% was partial remission.
Hence, it was proposed that favorable results could have been due
to the synergistic effect of the tested compounds (115). It has been
shown that 1,25D activity can be potentiated in prostate cancer
by using CYP24A1 inhibitors (122, 123). CYP24A1 is involved in
the catabolism of 1,25D (124) and its overexpression is associated
with poor prognosis of some human cancers (125–127).
These early clinical trials using high doses of 1,25D raised an
important issue of the maximum tolerable dose in clinical use. It
was proposed that a maximum dose of 1,25D is >100µg/week
intravenously and an oral dose of 0.15µg/kg/week. Commercially
available 1,25D can be used in high doses for oral administration,
however intravenous administration with high levels gives the best
therapeutic results (102). Several studies revealed that pharmaco-
kinetic dose escalation did not result in the escalation of systemic
exposure. Desirable linear relationship between dose and systemic
exposure was lost at doses>16µg/kg/week (128–130).
VARIABLE EX VIVO RESPONSES OF AML PATIENT’S BLASTS
TOWARD 1,25D OR VDA-INDUCED DIFFERENTIATION
There might be multiple reasons for the unsatisfactory results of
the above mentioned clinical treatments of AML patients using
1,25D or its analogs. One very important reason is that the patients
with AML were not stratified further into subgroups, despite the
fact that AML is not just one disease, but a heterogeneous group of
diseases with various underlying causes. Traditional classification
of AML introduced by French–American–British (FAB) hemato-
oncologists, which was based on morphology, immunochemistry,
and immunophenotyping of blast cells, divided AML into eight
subgroups (131). More recently, a new classification was proposed,
which includes cytogenetics and molecular diagnostics (132). So
far, there are more than 200 distinct mutations reported in AML
blasts (133), however some of them are more frequent than the
others.
Some of the mutations found in AML blasts have their inde-
pendent prognostic value, and therefore routine molecular genet-
ics analyses are implemented in diagnostic procedures nowadays
(134). The mutation, which has the highest prognostic impact
is the above mentioned t(15;17), which leads to the fusion pro-
tein PML–RARα. This mutation is characteristic of M3 subtype of
AML (according to FAB classification), the subtype which renders
this leukemia susceptible to ATRA treatment and confers almost
80% survival after 10 years from diagnosis (135). Another exam-
ple of an abnormality with a good prognostic value is mutations
in nucleophosmin 1 (NPM1), which are present in about 30% of
AML patients. NPM1 is a protein which normally shuttles between
cytosol and nucleus where it chaperons transport of other pro-
teins, but when mutated is retained in the cytosol of the cell (136,
137). For patients with NPM1 mutations, the overall survival rate
after 10 years is about 52% (135). The good prognosis for the
above patients is limited to the individuals with wild-type FLT3. In
contrast, FLT3 mutations and specifically internal tandem dupli-
cations (ITD), confer a bad prognosis for patients (135). Wild-type
FLT3 is important in normal hematopoiesis, where its activation is
strictly regulated by the FLT3 ligand. FLT3–ITD mutation causes
Table 2 | Clinical trials using vitamin D compounds in AML patients (117).
Vitamin D compound No. of patients Response Reference
Alfacalcidol 2 Transient hypercalcemia, decrease of blasts in bone marrow Irino and Taoka (109)
Alfacalcidol 2 One minor response in AML M4 patient Takahashi et al. (111)
Alfacalcidol 1 One major response Nakayama et al. (110)
Alfacalcidol, cytarabine, INFα, retinoids 15 5 Hellström et al. (108)
Alfacalcidol, cytarabine, 13-cis-retinoic acid 15 5 Hellström et al. (112)
1,25D, cytarabine, 13-cis-retinoic acid 26 15 Response: 58% Ferrero et al. (116)
1,25D, cytarabine, hydroxyurea 29 13 Complete remissions, 10 partial remissions, response: 79% Slapak et al. (115)
Alfacalcidol 11 17% Complete remission, 45% partial remission, response: 18% Petrini et al. (113)
Alfacalcidol 21 Complete remission 17% Petrini et al. (114)
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Table 3 | Impact of selected cytogenetic abnormalities on disease
outcome based on Ref. (135, 139).
Cytogenetic or
molecular abnormality
Fusion protein or
mutated protein
OS after
10 years (%)
t(15;17) PML–RARα 77–81
t(8;21) AML1–ETO 61–65
CEBPA biallelic C/EBPα 51
FLT3 wt; NPM1 mut Nucleophosmin 52
t(9;11) MLLT3–MLL 39–59
t(6;9) DEK/NUP214 27–29
FLT3–ITD; NPM1 wt FLT3–ITD 10
−7/del(7q) – 10
−5/del(5q) – 6
OS, overall survival.
constitutive activation of the receptor and enhanced proliferative
potential of blast cells (138). This mutation is present in 20–27%
of AML patients, whose overall survival rate after 10 years is only
10% (135). The above examples show clearly how high is the
impact of individual mutation for the blast cell fate. The overview
of the prognostic significance of selected recurring chromosomal
and molecular abnormalities based on the study conducted on
younger adult patients (135, 139) is given in Table 3. It should
be remembered that the combinations of multiple mutations are
very common in AML patients (134) and that the higher num-
ber of abnormalities carried by a patient worsens an individual
prognosis (139).
Therefore, we hypothesized that the mutations present in AML
blasts could also influence their susceptibility to 1,25D-induced
monocytic differentiation. In order to test this hypothesis, we per-
formed two sets of experiments using blasts from the peripheral
blood of freshly diagnosed AML patients. These blasts were ex vivo
exposed to either 1,25D or low calcemic VDAs and then tested
using flow cytometry for the presence of monocytic differenti-
ation marker CD14. In the first series of experiments, the blast
cells from 32 patients (140), while in the second series from 56
patients (141) were studied. The analysis of data revealed that the
cells with mutated FLT3 were less responsive to 1,25D-induced dif-
ferentiation than the remaining blast cells (140, 141). Therefore,
we wanted to further investigate the nature of that correlation.
For this purpose, we used two AML cell lines, which carry FLT3–
ITD mutations: MV4–11 cell line has mutation in both, while
MOLM-13 in one allele (142). Our in vitro experiments revealed
that these two cell lines were responsive to 1,25D and to VDAs,
which pointed out that the correlation observed in AML patients
blasts with FLT3 mutation, the low differentiation response was
not caused by mutation itself, but by other, unknown to us at this
moment reasons (90). In our ex vivo experiments, we also observed
that the blast cells from AML patients, having NPM1 mutation had
a tendency to differentiate better than other blasts. However, many
patients have both of the above mutations and in our experiments,
the blasts with both mutations differentiated better in response to
1,25D than the blasts with FLT3–ITD, but weaker than the ones
with mutated NPM1 alone.
In our ex vivo experiments, we also observed that deletion of a
short arm or whole of chromosome 7 [−7/del(7q)] in AML blast
cells correlated with a stronger differentiation response, in com-
parison with other blast cells. Thus, we hypothesized that there
could be a gene located in the short arm of chromosome 7, which is
responsible for degradation of 1,25D. The gene which supposedly
could take part in such process is the one which encodes NADPH-
cytochrome P450 reductase (CYPOR), an enzyme responsible for
electron transfer to cytochrome P450, and vital in the metabolism
of drugs and steroid production in humans. From our further
experiments, we documented that indeed the expression of this
gene and the level of an enzyme in AML cells was strongly upreg-
ulated by RA, but also to some extent by 1,25D (143). Another
conclusion which could be drawn from our experiments is that
blasts from only few patients differentiate in response to 1,25D
as strongly as model AML cell lines, such as HL60, MV4–11,
MOLM-13, U-937, or NOMO-1 (90, 140, 144). Together, our
results indicate that responses of individual patients’ blast cells
to 1,25D are variable and that due to the heterogeneity of the
disease and overlapping mutations, statistical analysis is very dif-
ficult. In order to find the impact of individual mutation, very big
groups of patients should be included in the ex vivo tests. More-
over, one should remember that ex vivo tests are fundamentally
simple in comparison to the clinical trials, where the AML blast
cells, which should get differentiated in response to 1,25D or its
analogs, are present in a living body with an immune system and
other accompanying diseases. This explains why the small clinical
trials described above produced so many inconclusive results.
RA AND 1,25D COMBINATION TREATMENTS
The idea of using 1,25D or VDAs in combination with retinoids
to elicit better anti-tumor effects, than treating patients with
1,25D or RA alone to produce synergistic effects was suggested
in the past (86). The studies were conducted on myeloblas-
tic cell line (HL60) and APL cell line (NB4) using VDA: 20-
epi-22oxa-24a,26a,27a-tri-homo-1,25(OH)2D3 (KH1060) and 9-
cis-RA, which promoted the differentiation and inhibited the
growth of the cell lines. This was found to be achieved by
reduced anti-apoptotic bcl-2 and increased pro-apoptotic bax
expression (145, 146). Few other VDAs like 1,25-(OH)2-δ-16-23-
yne-cholecalciferol and 1,25-(OH)2-23-yne-cholecalciferol, were
found to promote much more differentiation than 1,25D, with
very little effect on the calcium-phosphate homeostasis. When
used in combination with RA in vitro on HL60 cells, an addi-
tive pro-differentiating effect was observed (147). When 9-cis-RA
was used with 1,25D in combination therapy, which induced gran-
ulocytic and/or monocytic differentiation, TGF-β1 was identified
as the secondary mediator in AML cells (148).
THE SEARCH FOR A MOLECULAR BASIS OF AN
RA-REGULATED TRANSCRIPTION OF VDR
One of the AML cell lines being used in our laboratory is KG-1,
which is unresponsive to 1,25D or VDAs (149, 150), but responsive
to RA. As presented before, RA inhibited clonal growth in KG-1
to a higher degree than in HL60 cells (6, 151) and the inhibitory
effect of RA on the growth of KG-1 cells was irreversible even
after its removal from the cells (151). We documented from our
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experiments that these cells respond to ATRA with upregulation
of VDR gene expression, which restores their sensitivity to 1,25D.
Constitutive expression of VDR gene was 10–12 times lower in
KG-1 cells, in comparison with 1,25D-responsive HL60 cells, and
after ATRA treatment it increased by about 8 times. Surprisingly,
our experiments documented that HL60 cells respond to ATRA
with downregulation of VDR gene expression (150).
The gene which encodes human VDR was cloned in 1988 (152).
This gene is located on chromosome 12 and spans about 100 kb of
genomic DNA. Translation of VDR protein starts from exon 2, and
due to T to C polymorphism which eliminates the most 5′-located
ATG codon, the translation starts from the second in-frame ATG
codon in some individuals. As a result, two variants of VDR pro-
tein exist, one three amino-acids shorter (424 aa) than the other
(427 aa) (153), and the shorter variant was found to exert higher
transcriptional activity due to a better contact with the human
basal transcription factor IIB (TFIIB) (154, 155). Knowing that,
we hypothesized that low activity of 1,25D in KG-1 cells, and high
activity in HL60 cells, might have resulted from the different VDR
protein variants in these cells. Therefore, the exon 2 was sequenced
in the above cell lines, and the results indicated that KG-1 cell line
is indeed homozygous in two longer variants of VDR, while HL60
cells have one longer and one shorter variant. However, U-937
cell line which was also found to be homozygous in two longer
variants of VDR, differentiated in vitro in response to 1,25D or
VDAs, showing that length of VDR is not the only reason for KG-1
cells’ resistance to 1,25D. The remaining cell lines used in our lab-
oratory, namely NB4, MV4–11, MOLM-13, and NOMO-1 were
found to be heterozygous with respect to VDR protein length,
while THP-1 is homozygous in two shorter variants of VDR (our
unpublished data).
Characterization of factors that regulate expression of the VDR
gene at the transcriptional level is hampered because of the com-
plexity of the promoter region. To date, several small non-coding
exons have been identified (exons 1a–f) in the large regulatory
region encompassing 65 kb upstream of the so-called coding
region of VDR gene (exons 2–9) (Figure 1). Numerous combina-
tions of the 5′-UTR of VDR are formed by an alternative splicing
and/or different promoter usage. The main promoter of the VDR
gene is the region associated with exon 1a (153). This promoter is
characterized by the lack of canonical TATA- and CAAT-box and
the presence of multiple specificity protein 1 (Sp1)-binding sites
in a GC-rich region localized ~100 bp upstream of the transcrip-
tional start site (TSS) present in exon 1a. This promoter region
contributes to the constitutive VDR expression in multiple tissues
and cells and has been shown to be predominant in human kidney,
intestine, and bone (156). The 1a promoter region not only regu-
lates the transcripts originating from exon 1a but also from exon
1d (156) which can be a result of the imprecise TSS localization
typical for the TATA-less promoters. Exon 1d contains an alter-
native ATG codon and transcripts containing this exon have the
potential to encode N-terminally extendedVDR isoforms (VDRB1
and VDRB2) which have been shown to be co-expressed with the
canonical VDR isoform (VDRA) (157, 158).
In contrast to the constitutive activity of 1a promoter region, the
promoter associated with exon 1f, localized in the furthest distance
from the coding region, drives expression of transcripts which
have been shown to be tissue and cell-type specific. Transcripts
originating from exon 1f are present in kidney tissue, parathyroid
adenoma tissue, and in intestinal cell line (LIM 1863), which, as it
has been noticed in the original work, represent the major target
for calcitropic effects of 1,25D (156). The 1f promoter has been
reported to contain sequences binding multiple transcriptional
factors such as cAMP response element-binding protein (CREB),
Wilms tumor protein (Wt-1), and Caudal type homeobox 2 (Cdx-
2) (159, 160). In contrast to cell- and tissue-restricted expression of
the corresponding transcripts, the 1f promoter region, when fused
to reporter genes alone, displays its activity in variety of cell types
which might suggest the existence of a distal regulatory region
associated with the 1f promoter and regulating its tissue-specific
activity.
In view of the scope of this review, the most interesting issue
is the responsiveness of the VDR promoter(s) to hormonal reg-
ulation, especially by RA. Unlike the above described promoter
regions (1f and 1a), the TATA-containing promoter associated
with 1c exon (proximal to the coding region of VDR) has proven
to be regulated by 1,25D, RA, estrogens, and phytoestrogens which
upregulate the promoter activity in breast cancer cell lines (161).
The sequence of 1c promoter does not contain any estrogen
or 1,25D response elements but, similar to promoter 1a, con-
tains Sp1 binding sites localized in GC-rich region. Three Sp1
consensus binding sites were identified to independently confer
responsiveness to 1,25D, estrogens, and resveratrol (162).
According to our observations, the regulation of the activity of
1c promoter cannot be the only explanation for the different tran-
scriptional activity of VDR gene observed in HL60 and KG-1 in
response to RA, because the predominant types of VDR transcripts
observed in these cells contain exon 1a which indicates the use of
the 1a promoter region or promoter(s) further upstream exon 1a
in regulatingVDR expression in these cells. This would suggest that
the regulatory element that confers the responsiveness to RA may
not be localized in the promoter itself but rather in a cis-element
FIGURE 1 | Organization of humanVDR locus. Black boxes represent protein coding exons, gray – non-coding exons localized in the regulatory region of the
gene. Horizontal arrows indicate transcriptional start sites. White boxes represent promoter regions, white oval – the RA-responsive cis-regulatory element.
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cooperating with the promoter. One such element had been dis-
covered during the initial characterization of the VDR promoters
and is localized in an intron between exon 1c and exon 2 of VDR
gene (153). This element has been shown to mediate increased
activity of 1c promoter in response to RA and, more interest-
ingly, was able to transfer the RA-response to an unrelated viral
promoter proving its potential to regulate other promoters in the
locus. It will be very interesting to fully characterize this element
and perhaps to identify other enhancers/silencers present in VDR
regulatory region and their interactions with the VDR promoters.
This area of research seems to be somewhat neglected, probably
due to the complexity and the size of theVDR regulatory region but
the aid of techniques enabling the characterization of interactions
between distal DNA domains, such as chromosome conformation
capture (163) should provide new clues to fully characterize the
regulation of VDR transcription in different cell types. Since we
suppose that finding the mechanism of transcriptional up- and
down-regulation of VDR gene in response to ATRA might be rele-
vant for differentiation therapy of AML patients, the search for the
regulatory elements in VDR gene is underway in our laboratories.
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